The short version of NR1D1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Viktor Antonov (Bulgarian: Виктор Антонов; 5 February 1972 – 7 February 2025) was a Bulgarian artist, video game designer, writer, and worldbuilder who worked on numerous first-person shooter (FPS) games. In 2017, Blake Hester wrote for Vice that Antonov "has created disturbing, memorable, and unique worlds" which "conjure images of cyberpunk metropolises and grim London alleyways." Antonov's first game credits were at Xatrix Entertainment, for Redneck Rampage (1997), Redneck Deer Huntin' (1998), Redneck Rampage Rides Again (1998), and Kingpin: Life of Crime (1999). At Valve, he worked on Counter-Strike: Source (2004), Half-Life 2 (2004), and Half-Life 2: Lost Coast (2005). As art director of Half-Life 2, he principally designed its dystopian setting of City 17: a decaying Eastern European city occupied by the Combine alien empire, featuring Soviet-era Brutalist buildings and alien structures similar to panopticons which constitute the Combine's surveillance state. Antonov was temporarily art director of Valve's Team Fortress 2 (2007). While developing Dark Messiah of Might and Magic (2006) and Dishonored (2012) at Arkane Studios, Antonov worked on films and wrote a graphic novel. He principally designed Dishonored's setting of Dunwall, a labyrinthine dystopian city with steampunk Victorian and Gothic buildings; it and City 17 are often considered some of the best worlds ever made for video games.
== Background == Plants and animals alike both use small polypeptides for signaling in cell-to-cell communication. CLAVATA3/Embryo Surrounding Region-Related, also known as a plant peptide hormone, signaling is important for cell to cell signaling but also long distance communication. These two actions are especially important for plant cells because they are stationary and must perform cell expansion. In multicellular organisms, cell-to-cell communication has been found to be very crucial for many growth processes that occur inside the organism. The 12 or 13 amino acid polypeptides are the mature forms of the CLE proteins that are derived from the conserved CLE domains. More and more CLE genes are being identified with more research being conducted in this area. CLE genes have not only been found in seed plants but also in lycophytes, bryophytes, and green algae.
Within the international relations literature, international organizations facilitate cooperation between states by reducing transaction costs, providing information, making commitments more credible, establishing focal points for coordination, facilitating the principle of reciprocity, extending the shadow of the future, and enabling interlinkages of issues, which raises the cost of noncompliance. States may comply with the decisions of international organizations, even when they do not want to, for rational cost-benefit calculations (to reap concrete rewards of future cooperation and avoid punishment) and normative reasons (social learning and socialization). International organizations vary in terms of: inclusive or exclusive membership; broad or narrow scope; equal or unequal control by members; precision and flexibility of rules; hard or soft obligations; and delegation of power to the international organization. Other examples of international organizations include the UN General Assembly, the World Trade Organization, the African Development Bank, the UN Economic and Social Council, the UN Security Council, the Asian Development Bank, the International Bank for Reconstruction and Development, the International Monetary Fund, the International Finance Corporation, the Inter-American Development Bank, and the United Nations Environment Programme.
Sources: en.wikipedia.org
== Composition history == The original commission for Higdon to compose her first opera, in collaboration with Scheer as librettist, came from the San Francisco Opera. Over the period of 2009 to 2011, the creators had searched for various subjects to adapt, which led to the choice of the novel Cold Mountain. However, complications related to securing the rights to adapt the novel, along with conflicts over financial demands and reports of clashes of working style with San Francisco Opera with respect to the creation of new operas, led to the lapsing of this commission. Santa Fe Opera subsequently rescued this commission, in conjunction with the Opera Company of Philadelphia (now Opera Philadelphia) and the Minnesota Opera. Scheer began to write the libretto in autumn 2011, and Higdon began to compose the music in 2012. Higdon used her personal background of having lived in the Appalachia region of the US to assist Scheer with rendering portions of his libretto in a style of speech more authentic to the region, when needed: "I helped Gene 'southernize' the libretto. Gene's from New York, and he wasn't sure how to shape the language for the characters, so I took care of it. Those speech patterns felt very familiar. Scheer estimated that 20 to 25% of the sung text in his libretto came directly from lines in the novel. Higdon took 20 months to complete her score. Workshops of the opera at the Curtis Institute of Music occurred in December 2012 for act 1 and in December 2013 for act 2. In advance of the premiere, four of the five scheduled Santa Fe Opera performances sold out.
== Surveillance == Comparitech Limited, a UK technology advisor, published "The world's most-surveilled cities" in August 2019. It assembled data on the number of closed-circuit television (CCTV) cameras installed in 120 global cities. It then ranked the cities by number of cameras per 1,000 inhabitants. China's cities were found to be the most surveilled. Bangkok was ranked 31 (1=most surveilled; 120=least surveilled), with an estimated 53,429 cameras installed, or 5.16 cameras per 1,000 inhabitants. Other ASEAN cities were ranked: Singapore, 11 (86,000 cameras); Ho Chi Minh City, 72 (6,150 cameras); Yangon, 76 (2,995 cameras); Jakarta, 77 (6,000 cameras); Hanoi, 79 (4,400 cameras); Kuala Lumpur, 106, (1,000 cameras).
Fundamentals of Oncology (1997; co‑editors: Miklós Kásler, István Ember, László Kopper, László Thurzó) Dictionary of Epidemiology (2003; co‑editor: Piroska V. Hajdú) The Health Status of the Hungarian Population at the Turn of the Millennium (2003) Preventive Medicine and Public Health (2006, 2012; first and second editions) Public Health Genomics (2013; co‑editors: Judit Sándor, Angela Brand) Public Health in Budapest (2014; co‑editor: Tamás Szentes) Health Diplomacy (2014; co‑editors: Mihály Kökény, Ilona Kickbusch) Public Health Medicine (2015; co‑editors: István Kárpáti, György Paragh) Preventive Services in Primary Care (2017; co‑editor: Magor Papp) Preventive Medicine and Public Health (third edition, 2023; co‑editors: István Kiss, Edit Paulik, János Sándor, Zoltán Ungvári)
Peptide nucleic acids (PNAs) are synthetic oligonucleotides in which the sugar-phosphate backbone of the DNA or RNA is replaced by a neutral N-(2-aminoethyl)-glycine peptide-like backbone. This allows PNAs to hybridize with complementary DNA or RNA with high affinity and specificity, maintaining their ability to be amplified via polymerase chain reaction (PCR). Unlike DNA/RNA, PNAs are able to resist degradation by nucleases and proteases. In a PNA-encoded library system, unique PNA sequences serve as molecular tags that are covalently attached to small molecules that are produced using combinatorial methods that generate large collections of related compounds. These PNA tags act as barcodes that encode the identity of the PNA allowing for downstream identification. PNA libraries are synthesized using solid-phase peptide synthesis (SPPS), allowing library assembly on resin similar to other peptide libraries. This contrasts with DNA-encoded libraries, which often require enzymatic ligation steps and can be limited by the chemical properties of DNA. The neutrality and stability of the PNA backbone means that PNA tags can tolerate conditions that might degrade DNA tags, and the strong hybridization to complementary nucleic acids which allows PNA tags to be decoded wither by direct hybridization or by conversion into DNA, which can then be amplified and analyzed ,<ref. PNA-encoded libraries have been used in several different formats, including microarray hybridization, selection against biological targets, and PCR-based decoding following selection.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.